Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 601 to 605 of 605 total matches.
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
that persons with a history of anaphylaxis to a vaccine,
drug, or food not receive the Pfizer-BioNTech vaccine ...
The FDA has issued an Emergency Use Authorization
(EUA) for the Pfizer-BioNTech mRNA-based vaccine
for prevention of COVID-19 in persons ≥16 years old.
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
formulations for 2023-2024. Med Lett Drugs Ther 2023;
65:167.
3. F Dubovsky. Data in support of Novavax XBB ...
A new 2023-2024 formulation of the adjuvanted
protein subunit COVID-19 vaccine manufactured by
Novavax that was developed to more closely target
currently circulating SARS-CoV-2 variants has been
made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12
years old. The original formulation of the Novavax
vaccine is no longer authorized for use in the US.
In September, updated formulations of the mRNA
COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were
licensed by the FDA for use in persons ≥12 years old
and...
Med Lett Drugs Ther. 2023 Nov 13;65(1689):182-3 doi:10.58347/tml.2023.1689b | Show Introduction Hide Introduction
Cologuard Plus — An At-Home Stool DNA Test for Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • May 12, 2025 (Issue 1728)
trial
1. A stool DNA test (Cologuard) for colorectal cancer screening.
Med Lett Drugs Ther 2014; 56 ...
The FDA has approved Cologuard Plus (Exact
Sciences), a new at-home multitarget stool DNA test,
for colorectal cancer (CRC) screening in average-risk
adults ≥45 years old. Cologuard, the first FDA-approved
multitarget stool DNA test, has been available
since 2014.
Med Lett Drugs Ther. 2025 May 12;67(1728):73-5 doi:10.58347/tml.2025.1728a | Show Introduction Hide Introduction
COVID-19 Update: Novavax Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
formulations
for 2024-2025. Med Lett Drugs Ther 2024; 66:151.
4. COVID-19 Real-Time Learning Network. COVID ...
A 2024-2025 formulation of the Novavax adjuvanted
protein subunit COVID-19 vaccine that more
closely targets currently circulating SARS-CoV-2
variants is available now under an FDA Emergency
Use Authorization (EUA) for use in persons ≥12
years old. The 2024-2025 formulations of the
mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were licensed by the FDA last month for use in persons ≥12
years old and made available under EUAs for use in
persons 6 months to 11 years old.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):175-6 doi:10.58347/tml.2024.1714d | Show Introduction Hide Introduction
Shield — A Blood Test for Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025 (Issue 1730)
– an at-home stool DNA test for colorectal
cancer screening. Med Lett Drugs Ther 2025; 67:73.
9. TR Church et ...
The FDA has approved Shield (Guardant), a DNA
blood test, for colorectal cancer (CRC) screening
in average-risk adults ≥45 years old. Shield is the
second blood-based DNA test to be approved for CRC
screening; ColoHealth (formerly Epi proColon) was
approved in 2016.
Med Lett Drugs Ther. 2025 Jun 9;67(1730):90-2 doi:10.58347/tml.2025.1730b | Show Introduction Hide Introduction